Zacks Research Comments on Pacira BioSciences, Inc.’s FY2026 Earnings (NASDAQ:PCRX)

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Zacks Research issued their FY2026 earnings per share estimates for shares of Pacira BioSciences in a note issued to investors on Thursday, March 21st. Zacks Research analyst R. Department anticipates that the company will post earnings of $3.33 per share for the year. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.22 per share.

Several other equities research analysts have also recently weighed in on PCRX. Needham & Company LLC reiterated a “buy” rating and set a $45.00 price target on shares of Pacira BioSciences in a research report on Friday, March 1st. TheStreet upgraded Pacira BioSciences from a “d+” rating to a “c” rating in a research report on Thursday, February 29th. Royal Bank of Canada decreased their price target on Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating on the stock in a research report on Friday, March 1st. Raymond James began coverage on Pacira BioSciences in a research report on Wednesday, December 20th. They set an “outperform” rating and a $42.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $57.00 price target on shares of Pacira BioSciences in a research report on Monday, March 4th. Eleven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $49.50.

Pacira BioSciences Trading Down 2.5 %

Shares of Pacira BioSciences stock opened at $28.51 on Monday. The stock’s 50-day simple moving average is $30.27 and its 200 day simple moving average is $30.35. Pacira BioSciences has a 52-week low of $25.93 and a 52-week high of $48.60. The stock has a market capitalization of $1.33 billion, a P/E ratio of 35.20 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.17 and a current ratio of 5.24.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, February 29th. The company reported $0.71 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.71. Pacira BioSciences had a return on equity of 12.81% and a net margin of 6.22%. The business had revenue of $181.24 million for the quarter, compared to analysts’ expectations of $180.60 million.

Insider Buying and Selling

In related news, Director Gary W. Pace sold 90,000 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $30.60, for a total value of $2,754,000.00. Following the transaction, the director now directly owns 22,127 shares in the company, valued at $677,086.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Pacira BioSciences news, Director Gary W. Pace sold 1,066 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total value of $31,628.22. Following the completion of the sale, the director now owns 140,384 shares of the company’s stock, valued at $4,165,193.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gary W. Pace sold 90,000 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $30.60, for a total value of $2,754,000.00. Following the completion of the sale, the director now directly owns 22,127 shares of the company’s stock, valued at approximately $677,086.20. The disclosure for this sale can be found here. 6.60% of the stock is owned by company insiders.

Institutional Trading of Pacira BioSciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. boosted its stake in shares of Pacira BioSciences by 8.5% during the second quarter. Ameritas Investment Partners Inc. now owns 3,762 shares of the company’s stock valued at $151,000 after purchasing an additional 294 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Pacira BioSciences by 1.3% during the second quarter. MetLife Investment Management LLC now owns 23,990 shares of the company’s stock valued at $961,000 after purchasing an additional 319 shares during the period. Stephens Inc. AR boosted its stake in shares of Pacira BioSciences by 3.6% during the first quarter. Stephens Inc. AR now owns 10,470 shares of the company’s stock valued at $427,000 after purchasing an additional 360 shares during the period. ProShare Advisors LLC boosted its stake in shares of Pacira BioSciences by 3.9% during the second quarter. ProShare Advisors LLC now owns 10,102 shares of the company’s stock valued at $405,000 after purchasing an additional 376 shares during the period. Finally, Segall Bryant & Hamill LLC boosted its stake in shares of Pacira BioSciences by 0.4% during the second quarter. Segall Bryant & Hamill LLC now owns 94,444 shares of the company’s stock valued at $3,784,000 after purchasing an additional 397 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.